Skip to main content

Table 2  KRAS  mutation frequency in the investigated subcohort (  KRAS  Wild type: 128 (63.7%),  KRAS  Mutation 73 (36.3%))

From: Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group

   

relative frequency of occurrence (%)

absolute frequency of occurrence

CODON 12 mutation:

   

Aspartate (G12D)

c.35G>A

12,4

25

Valine (G12V)

c.35G>T

6,5

13

Alanine (G12A)

c.35G>C

3,4

7

Cysteine (G12C)

c.34G>T

3

6

Serine (G12S)

c.34G>A

3

6

Arginine (G12R)

c.34G>C

0,5

1

CODON 13 mutation:

   

Aspartate (G13D)

c.38G>A

7,5

15